InMed Pharmaceuticals, Inc.

How big is InMed Pharmaceuticals, Inc.?

As of Jun 18, InMed Pharmaceuticals, Inc. has a market capitalization of 2.85 million, categorizing it as a Micro Cap company, with net sales of 4.91 million and a net profit loss of 8.32 million over the last four quarters. As of June 2024, the company reported shareholder's funds of 9.21 million and total assets of 11.82 million.

Market Cap: As of Jun 18, InMed Pharmaceuticals, Inc. has a market capitalization of 2.85 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, InMed Pharmaceuticals reported net sales of 4.91 million. During the same period, the company incurred a net profit loss of 8.32 million.<BR><BR>Balance Sheet Snapshot: As of June 2024, InMed Pharmaceuticals reported shareholder's funds of 9.21 million and total assets amounting to 11.82 million.

What does InMed Pharmaceuticals, Inc. do?

InMed Pharmaceuticals, Inc. is a pre-clinical-stage biopharmaceutical company focused on developing cannabinoid-based therapies. As of March 2025, it has a market cap of $2.85 million, with net sales of $1 million and a net loss of $2 million.

Overview:<BR>InMed Pharmaceuticals, Inc. is a pre-clinical-stage biopharmaceutical company specializing in the research and development of cannabinoid-based therapies within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 2.85 Million (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.61 <BR>Return on Equity: -118.37% <BR>Price to Book: 0.41 <BR><BR>Contact Details:<BR>Address: SUITE 310, 815 W. HASTINGS STREET, VANCOUVER BC : V6C 1B4 <BR>Tel: 1 604 6697207 <BR>Website: https://www.inmedpharma.com/

Who are in the management team of InMed Pharmaceuticals, Inc.?

As of March 2022, the management team of InMed Pharmaceuticals, Inc. includes Dr. William Garner (Independent Chairman), Mr. Eric Adams (President and CEO), and Independent Directors Mr. Adam Cutler, Mr. Andrew Hull, and Ms. Catherine Sazdanoff. They oversee the company's strategic direction and operations.

As of March 2022, the management team of InMed Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. William Garner, who serves as the Independent Chairman of the Board.<BR>- Mr. Eric Adams, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Adam Cutler, who is an Independent Director.<BR>- Mr. Andrew Hull, who is also an Independent Director.<BR>- Ms. Catherine Sazdanoff, who serves as an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Should I buy, sell or hold InMed Pharmaceuticals, Inc.?

Is InMed Pharmaceuticals, Inc. overvalued or undervalued?

As of September 23, 2022, InMed Pharmaceuticals, Inc. is considered a risky investment due to its negative P/E ratio, poor return metrics, and significant year-to-date stock decline of -50.21%, indicating it may be overvalued compared to peers like Plus Therapeutics, Inc.

As of 23 September 2022, the valuation grade for InMed Pharmaceuticals, Inc. moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued, given its negative P/E ratio and poor return metrics. Key ratios include a Price to Book Value of 0.49, an EV to EBIT of 0.10, and an EV to EBITDA of 0.11, all suggesting that the company is struggling to generate positive returns.<BR><BR>InMed Pharmaceuticals is compared to peers such as Plus Therapeutics, Inc., which has a significantly worse EV to EBITDA ratio of -3.3801, indicating that InMed is somewhat better positioned despite both being classified as risky. However, the company's recent stock performance has been dismal, with a year-to-date return of -50.21% compared to the S&P 500's positive return of 12.22%, reinforcing the notion that the stock is overvalued in the current market context.

Is InMed Pharmaceuticals, Inc. technically bullish or bearish?

As of September 12, 2025, InMed Pharmaceuticals, Inc. is in a bearish trend, indicated by negative signals from moving averages and Bollinger Bands, with a year-to-date return of -50.21%, significantly underperforming the S&P 500's 12.22%.

As of 12 September 2025, the technical trend for InMed Pharmaceuticals, Inc. has changed from mildly bearish to bearish. The current stance is bearish, with key indicators supporting this view including a bearish signal from the daily moving averages and a bearish reading from the KST on the weekly timeframe. Although the MACD shows mildly bullish signals on both weekly and monthly charts, the overall trend remains bearish due to the prevailing bearish signals from Bollinger Bands and Dow Theory on the monthly timeframe. <BR><BR>In terms of performance, the stock has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -50.21% compared to the S&P 500's 12.22%, and a one-year return of -57.6% versus 17.14% for the index.